This paper, produced by an expert panel of the International Myeloma Working Group (IMWG) reviews the assessment of disease response and endpoints for clinical trials, and provides updated response categories of minimal residual disease negativity.
This paper, produced by the International Myeloma Working Group (IMWG), provides an updated definition of high-risk myeloma based on cytogenetics and provides recommendations for the optimum treatment for this group of myeloma patients.
This paper, written by the International Myeloma Working Group (IMWG), reviews the current evidence, and provides recommendations for the management of patients with relapsed myeloma.
This paper by the International Myeloma Working Group, reviews the available evidence and provides recommendations for the management of myeloma-related kidney disease
These guidelines, produced by an expert panel on behalf of the European Myeloma Network (EMN), provide recommendations for the management of the most common complications of myeloma, including bone and kidney disease.
Results from a Myeloma UK study, in which myeloma patients participated in a survey to determine individual preferences for treatment outcomes, have been published in The Oncologist. The survey, which was based on multicriteria decision analysis (MCDA) and swing weighting, asked patients to state their preference for the following outcomes of treatment; an increase in…
Advances in the Treatment of Paraproteinemic Neuropathy. Nobile-Orazio E et al. Curr Treat Options Neurol. 2017 Oct 16;19(12):43. doi: 10.1007/s11940-017-0479-9. Effectiveness of IHD with Adsorptive PMMA Membrane in Myeloma Cast Nephropathy: A Cohort Study. Sens F et al. Am J Nephrol. 2017 Oct 10;46(5):355-363. doi: 10.1159/000481461. [Epub ahead of print]. Interbody distraction and vertebral body reconstruction with polymethylmethacrylate for the treatment of pathological…
Elevation of Plasmin-α2-plasmin Inhibitor Complex Predicts the Diagnosis of Systemic AL Amyloidosis in Patients with Monoclonal Protein. Ishiguro K et al. Intern Med. 2017 Oct 11. doi: 10.2169/internalmedicine.8999-17. [Epub ahead of print]. Metachronous solitary plasmacytoma. Khosa R et al. BMJ Case Rep. 2017 Oct 19;2017. pii: bcr-2017-221780. doi: 10.1136/bcr-2017-221780. Intratubular amyloid in light chain cast nephropathy is a risk factor for…
A Comparative Assessment of Quality of Life in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation Through an Outpatient and Inpatient Model. Martino M et al. Biol Blood Marrow Transplant. 2017 Oct 12. pii: S1083-8791(17)30764-4. doi: 10.1016/j.bbmt.2017.09.021. [Epub ahead of print]. Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the…
Preclinical development of CD38-targeted [89Zr]Zr-DFO-daratumumab for imaging multiple myeloma. Ghai A et al. J Nucl Med. 2017 Oct 12. pii: jnumed.117.196063. doi: 10.2967/jnumed.117.196063. [Epub ahead of print]. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Kumar S et al. Blood. 2017 Oct 10. pii: blood-2017-06-788786. doi: 10.1182/blood-2017-06-788786. [Epub ahead of print]. Phase-I randomized trial of doxorubicin hydrochloride liposome injection versus…